摘要
目的:评价拉米夫定在乙型肝炎病毒(HBV)感染者治疗中的临床疗效和安全性。方法:查阅近几年有关中、外文献并结合自身临床实践,进行分析、评价。结果:拉米夫定能快速高效降低乙型肝炎病毒脱氧核糖核酸(HBV-DNA)水平。用于慢性乙型肝炎(CHB)及活动性肝硬化患者疗效较好,用于HBeAg阳性及丙氨酸转氨酶(ALT)正常的携带者的治疗效果不佳。结论:拉米夫定是治疗CHB的高效药物,应用方便、安全,不良反应少且轻微,耐受性好。
OBJECTIVE: To evaluate the clinical efficacy and safty of lamivudine in treatment of patients with HBV infections. METHODS: The analysis and evaluation were based on the review of literature, published in recent years, in combination with our clinical experience. RESULTS: Lamivudine could rapidly decrease the level of HBV-DNA in patients with hepatitis B and showed good therapeutic effect on chronic hepatitis B and active hepatocirrhosis, however, the effect was unsatisfactory on the carrier with positive HBeAg and normal ALT. CONCLUSION: Lumivudine is an effective agent in treating chronic hepatitis B and it is simple in use, safe, slight in ARDs and tolerable to patients.
出处
《中国医院用药评价与分析》
2001年第2期85-86,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
